Email updates

Keep up to date with the latest news and content from Alzheimer's Research & Therapy and BioMed Central.

Editorial

Right sizing funding for Alzheimer's disease

Todd E Golde1*, Bruce T Lamb2 and Douglas Galasko3

Author Affiliations

1 Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, College of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, PO Box #100159, FL 32608, USA

2 Department of Neurosciences, Lerner Research Institute, NC30, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

3 Department of Neurosciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037-M0624, USA

For all author emails, please log on.

Alzheimer's Research & Therapy 2011, 3:17  doi:10.1186/alzrt76

Published: 6 May 2011

First paragraph (this article has no abstract)

Finding novel, effective, Alzheimer's disease (AD) therapeutics has emerged as one of the major unmet medical needs in most developed nations [1,2]. AD is quite unique among highly prevalent diseases within these nations in that, despite tremendous advances in under-standing certain aspects of AD pathogenesis, there are no proven disease-modifying therapies and only minimally effective symptomatic therapies. Though many other prevalent diseases still cause tremendous morbidity and mortality, for many of them scientific and medical advances have led to novel therapies that alter disease course, reduce mortality, or at least significantly relieve symptoms for some period of time. Typically, these therapies are not panaceas, or true cures, but nevertheless significant therapeutic inroads have been made.